(2R,5S)-1-benzyl-5-ethyl-2-methylpiperazine | 906810-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,5S)-1-benzyl-5-ethyl-2-methylpiperazine
• 英文别名: (2S,5R)-2-ethyl-4-benzyl-5-methyl-piperazine；2(S)-ethyl-4-benzyl-5(R)-methylpiperazine；(2R,5S)-2-ethyl-4-benzyl-5-methyl-piperazine；(2R,5S)-1-Benzyl-5-ethyl-2-methylpiperazine
• CAS: 906810-50-2
• 化学式: C₁₄H₂₂N₂
• 分子量: 218.342
• InChiKey: WMQIYLJQZHLVOF-OCCSQVGLSA-N

物化性质

• 沸点：
  308.6±22.0 °C(Predicted)
• 密度：
  0.951±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R,5S)-1-benzyl-5-ethyl-2-methylpiperazine 在 palladium 10% on activated carbon 氢气 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 乙腈 为溶剂， 20.0 ℃ 、350.01 kPa 条件下， 生成 ((2S,5R)-2-ethyl-5-methyl-piperazin-1-yl)-acetic acid
  参考文献：
  名称：

  [EN] BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
  [FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEURS UTILISATIONS EN THÉRAPIE

  摘要：

  该发明涉及公式（I）的双环杂环化合物，或其互变异构体或立体化学同分异构体，N-氧化物，药用盐或其溶剂合物；其中R1、R2a、R2b、R3a、R3b、R5、R6、R7、R8、R9、p和E如本文所定义；以及包含该化合物的药物组合物，以及该化合物在治疗疾病（如癌症）中的用途。

  公开号：

  WO2012143726A1
• 作为产物：
  描述：

  tert-butyl (2S,5R)-4-benzyl-2-ethyl-5-methyl-3,6-dioxopiperazine-1-carboxylate 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 51.5h， 以93%的产率得到(2R,5S)-1-benzyl-5-ethyl-2-methylpiperazine
  参考文献：
  名称：

  WO2006/88837

  摘要：

  公开号：

文献信息

• Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
  申请人：Anilkumar N. Gopinadhan

  公开号：US20060217392A1

  公开（公告）日：2006-09-28

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、外消旋体或前药，或该化合物的药学上可接受的盐、溶剂化合物或酯，或该前药的药学上可接受的盐、溶剂化合物或酯，该化合物具有如式1所示的一般结构，或其药学上可接受的盐、溶剂化合物或酯。还公开了一种使用式1化合物治疗趋化因子介导的疾病的方法，例如缓解疗法、治疗疗法、预防性治疗某些疾病和情况，如炎症性疾病（非限制性例子包括牛皮癣），自身免疫性疾病（非限制性例子包括类风湿性关节炎、多发性硬化症），移植排斥（非限制性例子包括同种异体排斥、异种排斥），感染性疾病（例如结核性麻风），固定药物疹，皮肤迟发型超敏反应，眼科炎症，I型糖尿病，病毒性脑膜炎和肿瘤。
• NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY
  申请人：ROSENBLUM B. STUART

  公开号：US20080039474A1

  公开（公告）日：2008-02-14

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、消旋体或前药，或该化合物的药学上可接受的盐、溶剂化物或酯，或该前药的药学上可接受的盐、溶剂化物或酯，该化合物具有如公式1所示的一般结构，或其药学上可接受的盐、溶剂化物或酯。还公开了一种治疗趋化因子介导的疾病的方法，例如，缓解疗法、治疗性疗法、预防性疗法，用于治疗炎症性疾病（非限定性例子包括牛皮癣）、自身免疫性疾病（非限定性例子包括类风湿性关节炎、多发性硬化症）、移植排斥反应（非限定性例子包括同种移植排斥反应、异种移植排斥反应）、感染性疾病（例如，麻风结节病）、固定药物性皮疹、皮肤迟发型超敏反应、眼部炎症、1型糖尿病、病毒性脑膜炎和肿瘤，使用公式1的化合物。
• HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY
  申请人：Rosenblum B. Stuart

  公开号：US20080058343A1

  公开（公告）日：2008-03-06

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、外消旋体或该化合物的前药，以及该化合物的药物可接受的盐、溶剂合物或酯，或该前药的药物可接受的盐、溶剂合物或酯。该化合物的一般结构如公式1所示：或其药物可接受的盐、溶剂合物或酯。同时，本申请还公开了使用公式1的化合物治疗趋化因子介导的疾病的方法，例如，缓解疗法、治愈疗法、预防性治疗某些疾病和病况，例如炎症性疾病（非限定性示例包括牛皮癣）、自身免疫性疾病（非限定性示例包括类风湿性关节炎、多发性硬化症）、移植排斥（非限定性示例包括同种异体排斥、异种排斥）、感染性疾病（例如结核性麻风）、固定药物性皮疹、皮肤迟发型超敏反应、眼部炎症、1型糖尿病、病毒性脑膜炎和肿瘤。
• Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
  申请人：Zeng Qingbei

  公开号：US20060276448A1

  公开（公告）日：2006-12-07

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转动异构体、互变异构体、外消旋体或前药，或该化合物的药物可接受的盐或溶剂，或该前药的药物可接受的盐、溶剂或酯，该化合物具有如图式1所示的一般结构，以及其药物可接受的盐、溶剂或酯。本申请还公开了一种使用图式1的化合物治疗趋化因子介导的疾病的方法，例如，缓解疗法、治愈疗法、预防疗法，如炎症性疾病（非限制性示例包括牛皮癣），自身免疫性疾病（非限制性示例包括风湿性关节炎、多发性硬化症），移植排斥（非限制性示例包括同种异体移植排斥、异种移植排斥），感染性疾病（例如，结核性麻风），固定药物性皮疹，皮肤延迟型超敏反应，眼部炎症，1型糖尿病，病毒性脑膜炎和肿瘤。
• Heterocyclic substituted piperazines with CXCR3 antagonist activity
  申请人：Kim Heon Seong

  公开号：US20060276479A1

  公开（公告）日：2006-12-07

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、外消旋体或前药，或该化合物的药物可接受的盐、溶剂合物或酯类，或该前药的药物可接受的盐、溶剂合物或酯类，该化合物具有如公式1所示的一般结构，其中各种基团在此定义。还公开了一种治疗趋化因子介导疾病的方法，例如，治疗炎症性疾病（非限制性例子包括牛皮癣）、自身免疫性疾病（非限制性例子包括类风湿性关节炎、多发性硬化症）、移植排斥（非限制性例子包括同种异体排斥、异种移植排斥）、感染性疾病（例如，结核性麻风）、固定药物性皮疹、皮肤迟发型超敏反应、眼部炎症、1型糖尿病、病毒性脑膜炎和肿瘤，使用公式1的化合物。